Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555724 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00555724 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 40 participants.
The verdict
NCT00555724, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.
Interventions
- DRUG BIIB022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00555724
The ClinicalTrials.gov registry entry for NCT00555724 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIIB022 is the first listed.
NCT00555724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00555724 about?
NCT00555724 is a clinical study titled "Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors". Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.
What is the current status of trial NCT00555724?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-01. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00555724?
The interventions under investigation include: BIIB022 (DRUG).
Who is sponsoring clinical trial NCT00555724?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.